Calcium Aluminosilicate Anti-Diarrheal in Treating and Preventing Diarrhea in Patients With Metastatic Colorectal Cancer Receiving Irinotecan
Completed · Phase 2 · Has a placebo group
Conditions studied: Chemotherapeutic Agent Toxicity, Colorectal Cancer, Diarrhea
In brief
RATIONALE: Calcium aluminosilicate anti-diarrheal (CASAD) may help treat and prevent diarrhea caused by irinotecan. It is not yet known whether CASAD is more effective than a placebo in treating and preventing diarrhea in patients receiving irinotecan. PURPOSE: This randomized phase II trial is studying CASAD to see how well it works compared with a placebo in treating and preventing diarrhea in patients with metastatic colorectal cancer receiving irinotecan.
Key facts
- Study ID
- NCT00748215
- Run by
- M.D. Anderson Cancer Center
- People needed
- 100
- Starts
- 2009-02-04
- Expected to finish
- 2014-08-12
- Last updated by the study team
- 2020-12-02
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- CCOP - Columbia River Oncology Program — Portland, Oregon, United States
- M. D. Anderson Cancer Center at University of Texas — Houston, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.